Previous 10 | Next 10 |
home / stock / jnj / jnj articles
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive compa...
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks...
In a significant development, Johnson & Johnson (NYSE:JNJ) has agreed to pay a hefty sum to resolve a multi-state investigation into its talc-b...
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
A jury has ruled that Johnson & Johnson (NYSE:JNJ) must pay $260 million to an Oregon woman who claims to have developed mesothelioma from usin...
Monday, Johnson & Johnson (NYSE:JNJ) announced longer-term data from Phase 1/2 MajesTEC-1 study of Tecvayli (teclistamab-cqyv) showing deep and...
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this ar...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap...
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (ARCA:IYH), ...
News, Short Squeeze, Breakout and More Instantly...
Assa Abloy AB ADR (ASAZY) is expected to report for Q2 2024 First Horizon Corporation (FHN) is expected to report $0.37 for Q2 2024 Community Trust Bancorp Inc. (CTBI) is expected to report $1.03 for Q2 2024 Cohen & Steers Inc (CNS) is expected to report for Q2 2024 First Indu...
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on Aug...
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (&...